Neisseria meningitidis serogroup B vaccine development.

Autor: Caesar NM; University of the Sciences Philadelphia, McNeil Science and Technology Center, Department of Biological Sciences, 600 S 43rd Street, Philadelphia, PA 19104, USA. NCaesar@mail.usciences.edu, Myers KA, Fan X
Jazyk: angličtina
Zdroj: Microbial pathogenesis [Microb Pathog] 2013 Apr; Vol. 57, pp. 33-40. Date of Electronic Publication: 2013 Feb 14.
DOI: 10.1016/j.micpath.2013.02.003
Abstrakt: Neisseria meningitidis is an air-borne, gram-negative pathogen that actively invades its human host leading to the development of life-threatening pathologies. As one of the leading causes of death in the world, during an epidemic period N. meningitidis can be responsible for nearly 1000 new infections per 100,000 individuals. The bacterial species is further categorized into 13 serotypes, with five, A, B, C, W-135, and Y, being the most clinically relevant, causing the overwhelming majority of diseases. There are two contemporary, purified protein conjugate vaccines available that function by targeting serogroups A, C, W-135, and Y. Historically, serogroup B has posed a vaccination challenge; however, there are currently two vaccines in development able to target serotype B. This review will highlight N. meningitidis as a pathogen and explore the recent literature providing a current review of meningococcal vaccination development.
(Copyright © 2013 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: